University of Miami researchers report that supplements of the mineral selenium appear to reduce or slow the progression of HIV.
Deficiencies in selenium have been noted in HIV-positive patients, and evidence suggests that supplements of the nutrient can improve immune system function, the researchers report in the Jan. 22 issue of the Archives of Internal Medicine."Those individuals who were treated with selenium displayed no further progression of HIV disease, whereas those who were on placebo evidenced a continued increase in HIV viral load," said lead researcher and professor of psychology Barry E. Hurwitz.
Another expert said the importance of the findings should not be overstated, however.
"That a cheap micronutrient might help blunt the short-term progression of HIV infection is wonderful news and can offer an intervention for persons in care settings who are not yet eligible for, or do not yet have access to, potent antiretroviral therapies," said Dr. Sten H. Vermund, the Amos Christie Chair and director of the Vanderbilt Institute for Global Health at Vanderbilt University in Nashville, Tenn.
However, he stressed "by no means is selenium a treatment alternative, as the authors state, since the magnitude of benefit pales in comparison to that of antiretrovirals." Vermund was not involved in the study.
In the study, Hurwitz and colleagues randomly assigned 262 patients infected with HIV to 200 micrograms of selenium per day or placebo. Over the first nine months of the trial, the researchers monitored the patients' CD4 immune T-cell count (a measure of immune system health) and HIV viral load (the number of copies of the HIV virus in the blood).
Advertisement
Improvements linked to selenium supplementation were seen whether patients were taking HIV antiretroviral drugs or not, Hurwitz said. "The impact of selenium was seen over and above anti-HIV medications," he said.
Advertisement
There is a tremendous challenge in the treatment of HIV patients using conventional medications to achieve and maintain suppression of the disease, Hurwitz noted. "Taking one capsule of selenium a day is a simple and inexpensive and safe therapy that can be used, not as a replacement for HIV drugs, but as an adjunct therapy," he said.
Hurwitz believes that taking selenium can be particularly effective in HIV patients who don't adhere closely to their medications regimens. "Selenium could be a very important advance in adjunct therapy," he said.
Selenium has many unique qualities, he added. "It has many beneficial aspects that affect our health," Hurwitz said. "There have been findings that it may be beneficial to our immune system, and it is a highly potent antioxidant."
"Selenium is available, and it's ready to be implemented right now," Hurwitz added. "It's a simple, inexpensive adjunct therapy, and I think it's ready to have an impact right now."
One expert said the study did have some drawbacks, however.
"Most of the study subjects are African-American men, most are on antiretroviral therapy, and most have low or undetectable viral loads," noted Dr. David Margolis, a professor of medicine, microbiology and immunology and epidemiology at the University of North Carolina at Chapel Hill. Also, "many of the study subjects are lost to follow-up, potentially introducing unforeseen bias into the findings," Margolis said.
Most important, the relevant benefit -- increased CD4 cell count -- attributed to selenium is rather small, he said. "Further, the CD4 cell count of the study group has already been sufficiently reconstituted by antiviral [drug] therapy to prevent most clinical problems. While it is possible that selenium supplementation reduces the frequency of failure of antiviral therapy, much better evidence would be needed to prove this," he said.
It would be interesting to show that selenium slowed the progression of HIV disease in patients with high CD4 counts -- a group that currently might not be offered antiviral therapy, Margolis said. "Strategies to safely delay antiviral therapy would be welcomed by many patients and providers," he said.
But too much selenium can also harm patients, Margolis added. In fact, in very large doses, supplementation can be fatal.
"The tolerable upper level is said to be 400 micrograms a day for adults, and the average U.S. diet contains about 100 micrograms a day," Margolis said. "There is also some evidence that selenium may blunt the protective effect of statins in slowing cardiovascular disease, so patients on therapy for lipid disorders might wish to avoid selenium supplementation until there is better evidence that it is beneficial," he said.
Source: Bio-Bio Technology
SRI
